Press Enter to Main Content
您的瀏覽器似乎不支援JavaScript語法,但沒關係,這裡的JavaScript語法並不會影響到內容的陳述, 如需要選擇字級大小,IE6請利用鍵盤按住ALT鍵+ V → X → (G)最大(L)較大(M)中(S)較小(A)小,來選擇適合您的文字大小, 而IE7或Firefox瀏覽器則可利用鍵盤 Ctrl + (+)放大(-)縮小來改變字型大小,如需要回到上一頁可使用瀏覽器提供的 Alt+左方向鍵(←) 快速鍵功能,列印可使用瀏覽器提供的(Ctrl+P)功能。
  • facebook
  • line
  • twitter
  • Print
  • Back

Taiwan FDA and Malaysia NPRA signed the Collaboration document over Pharmaceutical regulations.

  • Data Source:Food and Drug Administration, Ministry of Health and Welfare
  • Created:2018-04-25
  • Last Updated:2018-04-25

In order to promote New Southbound Policy and allow the Taiwan pharmaceutical industry to better understand the relevant regulations in southbound countries for better market access, Taiwan Food and Drug Administration (TFDA) and the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia have signed the official collaboration document over pharmaceutical regulations on March 26th this year. The collaboration covers 5 main aspects, including:

  1. Information exchange.
  2. Technical cooperation.
  3. Experience sharing on implementation of policies or regulations.
  4. Holding periodical working meetings.
  5. Holding professional visits and activities as workshops/conferences.

The signing of this collaboration document has successfully expanded exchanges and formalized the cooperation between the pharmaceutical regulatory authorities of Taiwan and Malaysia. Based on the signed document, TFDA will continuously to facilitate regulation harmonization, exchange of scientific detection technologies, and laboratory verification collaboration with the NPRA, to gain their trust in Taiwan’s products. By building mutual trust, TFDA hopes to reduce the duplication of tests and inspections, simplify review process, and thus shorten the time for products to enter the markets in Malaysia and other southbound countries, connecting businesses and eventually promoting the development of pharmaceutical industry within the region.